1
|
Dratch L, Azage M, Baldwin A, Johnson K, Paul RA, Bardakjian TM, Michon SC, Amado DA, Baer M, Deik AF, Elman LB, Gonzalez-Alegre P, Guo MH, Hamedani AG, Irwin DJ, Lasker A, Orthmann-Murphy J, Quinn C, Tropea TF, Scherer SS, Ellis CA. Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts. J Neurol 2024; 271:733-747. [PMID: 37891417 DOI: 10.1007/s00415-023-12058-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 10/10/2023] [Accepted: 10/11/2023] [Indexed: 10/29/2023]
Abstract
The role of genetic testing in neurologic clinical practice has increased dramatically in recent years, driven by research on genetic causes of neurologic disease and increased availability of genetic sequencing technology. Genetic testing is now indicated for adults with a wide range of common neurologic conditions. The potential clinical impacts of a genetic diagnosis are also rapidly expanding, with a growing list of gene-specific treatments and clinical trials, in addition to important implications for prognosis, surveillance, family planning, and diagnostic closure. The goals of this review are to provide practical guidance for clinicians about the role of genetics in their practice and to provide the neuroscience research community with a broad survey of current progress in this field. We aim to answer three questions for the neurologist in practice: Which of my patients need genetic testing? What testing should I order? And how will genetic testing help my patient? We focus on common neurologic disorders and presentations to the neurology clinic. For each condition, we review the most current guidelines and evidence regarding indications for genetic testing, expected diagnostic yield, and recommended testing approach. We also focus on clinical impacts of genetic diagnoses, highlighting a number of gene-specific therapies recently approved for clinical use, and a rapidly expanding landscape of gene-specific clinical trials, many using novel nucleotide-based therapeutic modalities like antisense oligonucleotides and gene transfer. We anticipate that more widespread use of genetic testing will help advance therapeutic development and improve the care, and outcomes, of patients with neurologic conditions.
Collapse
Affiliation(s)
- Laynie Dratch
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Meron Azage
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Aaron Baldwin
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Kelsey Johnson
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Rachel A Paul
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Tanya M Bardakjian
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
- Sarepta Therapeutics Inc, Cambridge, MA, 02142, USA
| | - Sara-Claude Michon
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Defne A Amado
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Michael Baer
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Andres F Deik
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Lauren B Elman
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Pedro Gonzalez-Alegre
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
- Spark Therapeutics Inc, Philadelphia, PA, 19104, USA
| | - Michael H Guo
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Ali G Hamedani
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - David J Irwin
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Aaron Lasker
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Jennifer Orthmann-Murphy
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Colin Quinn
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Thomas F Tropea
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Steven S Scherer
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA
| | - Colin A Ellis
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce St, 3 West Gates Building, Philadelphia, PA, 19104, USA.
| |
Collapse
|
3
|
Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, Simuni T, Poon C, Schiess MC, Chou K, Park A, Bhatti D, Peterson C, Criswell SR, Rosenthal L, Durphy J, Shill HA, Mehta SH, Ahmed A, Deik AF, Fang JY, Stover N, Zhang L, Dewey RB, Gerald A, Boyd JT, Houston E, Suski V, Mosovsky S, Cloud L, Shah BB, Saint-Hilaire M, James R, Zauber SE, Reich S, Shprecher D, Pahwa R, Langhammer A, LaFaver K, LeWitt PA, Kaminski P, Goudreau J, Russell D, Houghton DJ, Laroche A, Thomas K, McGraw M, Mari Z, Serrano C, Blindauer K, Rabin M, Kurlan R, Morgan JC, Soileau M, Ainslie M, Bodis-Wollner I, Schneider RB, Waters C, Ratel AS, Beck CA, Bolger P, Callahan KF, Crotty GF, Klements D, Kostrzebski M, McMahon GM, Pothier L, Waikar SS, Lang A, Mestre T. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA 2021; 326:926-939. [PMID: 34519802 PMCID: PMC8441591 DOI: 10.1001/jama.2021.10207] [Citation(s) in RCA: 73] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 06/05/2021] [Indexed: 01/13/2023]
Abstract
Importance Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data. Objective To determine whether sustained urate-elevating treatment with the urate precursor inosine slows early PD progression. Design, Participants, and Setting Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. A total of 587 individuals consented, and 298 with PD not yet requiring dopaminergic medication, striatal dopamine transporter deficiency, and serum urate below the population median concentration (<5.8 mg/dL) were randomized between August 2016 and December 2017 at 58 US sites, and were followed up through June 2019. Interventions Inosine, dosed by blinded titration to increase serum urate concentrations to 7.1-8.0 mg/dL (n = 149) or matching placebo (n = 149) for up to 2 years. Main Outcomes and Measures The primary outcome was rate of change in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS; parts I-III) total score (range, 0-236; higher scores indicate greater disability; minimum clinically important difference of 6.3 points) prior to dopaminergic drug therapy initiation. Secondary outcomes included serum urate to measure target engagement, adverse events to measure safety, and 29 efficacy measures of disability, quality of life, cognition, mood, autonomic function, and striatal dopamine transporter binding as a biomarker of neuronal integrity. Results Based on a prespecified interim futility analysis, the study closed early, with 273 (92%) of the randomized participants (49% women; mean age, 63 years) completing the study. Clinical progression rates were not significantly different between participants randomized to inosine (MDS-UPDRS score, 11.1 [95% CI, 9.7-12.6] points per year) and placebo (MDS-UPDRS score, 9.9 [95% CI, 8.4-11.3] points per year; difference, 1.26 [95% CI, -0.59 to 3.11] points per year; P = .18). Sustained elevation of serum urate by 2.03 mg/dL (from a baseline level of 4.6 mg/dL; 44% increase) occurred in the inosine group vs a 0.01-mg/dL change in serum urate in the placebo group (difference, 2.02 mg/dL [95% CI, 1.85-2.19 mg/dL]; P<.001). There were no significant differences for secondary efficacy outcomes including dopamine transporter binding loss. Participants randomized to inosine, compared with placebo, experienced fewer serious adverse events (7.4 vs 13.1 per 100 patient-years) but more kidney stones (7.0 vs 1.4 stones per 100 patient-years). Conclusions and Relevance Among patients recently diagnosed as having PD, treatment with inosine, compared with placebo, did not result in a significant difference in the rate of clinical disease progression. The findings do not support the use of inosine as a treatment for early PD. Trial Registration ClinicalTrials.gov Identifier: NCT02642393.
Collapse
Affiliation(s)
- Michael A Schwarzschild
- Mass General Institute for Neurodegenerative Disease, Boston, Massachusetts
- Massachusetts General Hospital, Boston
| | | | | | | | - Rebecca Fitzgerald
- Parkinson's Foundation Research Advocates, Parkinson's Foundation, New York, New York
| | | | - Codrin Lungu
- Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
| | - Eric A Macklin
- Massachusetts General Hospital, Boston
- Harvard Medical School, Boston, Massachusetts
| | - Kenneth Marek
- Institute for Neurodegenerative Disorders, New Haven, Connecticut
| | - Dariush Mozaffarian
- Tufts School of Medicine and Division of Cardiology, Tufts Medical Center, Boston, Massachusetts
- Friedman School of Nutrition Science and Policy, Boston, Massachusetts
| | - David Oakes
- University of Rochester, Rochester, New York
| | | | - Ira Shoulson
- Department of Neurology, University of Rochester Medical Center, Rochester, New York
| | | | | | | | - Jason Aldred
- Inland Northwest Research, Spokane, Washington
- Selkirk Neurology, Spokane, Washington
| | | | | | | | - Claire Henchcliffe
- University of California, Irvine
- Weill Cornell Medical College, New York, New York
| | | | | | | | | | | | | | - Rajeev Kumar
- Rocky Mountain Movement Disorders Center, Englewood, Colorado
| | | | | | | | | | | | | | | | | | | | | | | | - David K Simon
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Tanya Simuni
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Cynthia Poon
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Mya C Schiess
- The University of Texas Health Science Center, Houston McGovern Medical School, Houston
| | | | - Ariane Park
- The Ohio State University Wexner Medical Center, Columbus
| | | | | | - Susan R Criswell
- Washington University School of Medicine in St Louis, St Louis, Missouri
| | | | | | - Holly A Shill
- Banner Sun Health Research Institute, Sun City, Arizona
- University of Arizona School of Medicine-Phoenix
| | | | | | | | - John Y Fang
- Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | | | | - Ashley Gerald
- University of Texas Southwestern Medical Center, Dallas
| | | | | | | | | | - Leslie Cloud
- VCU Parkinson's & Movement Disorders Center, Richmond, Virginia
| | | | | | | | | | - Stephen Reich
- University of Maryland School of Medicine, Baltimore
| | - David Shprecher
- Banner Sun Health Research Institute, Sun City, Arizona
- University of Arizona School of Medicine-Phoenix
| | - Rajesh Pahwa
- University of Kansas Medical Center, Kansas City
| | | | - Kathrin LaFaver
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Peter A LeWitt
- Henry Ford Hospital-West Bloomfield, West Bloomfield Township, Michigan
| | - Patricia Kaminski
- Henry Ford Hospital-West Bloomfield, West Bloomfield Township, Michigan
| | | | | | | | | | - Karen Thomas
- Sentara Neurology Specialists, Norfolk, Virginia
| | - Martha McGraw
- Center for Movement Disorders and Neurodegenerative Disease, Northwestern Medicine/Central DuPage Hospital, Winfield, Illinois
| | - Zoltan Mari
- Cleveland Clinic-Las Vegas, Las Vegas, Nevada
| | | | | | - Marcie Rabin
- Atlantic Neuroscience Institute, Summit, New Jersey
| | - Roger Kurlan
- Atlantic Neuroscience Institute, Summit, New Jersey
| | | | - Michael Soileau
- Texas Movement Disorder Specialists, Georgetown
- Scott & White Healthcare/Texas A&M University, Temple
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Sushrut S Waikar
- Boston University School of Medicine, Boston, Massachusetts
- Boston Medical Center, Boston, Massachusetts
| | - Anthony Lang
- University of Toronto, Toronto, Ontario, Canada
- Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada
| | | |
Collapse
|
5
|
Spotorno N, Hall S, Irwin DJ, Rumetshofer T, Acosta-Cabronero J, Deik AF, Spindler MA, Lee EB, Trojanowski JQ, van Westen D, Nilsson M, Grossman M, Nestor PJ, McMillan CT, Hansson O. Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. Radiology 2019; 293:646-653. [PMID: 31617796 PMCID: PMC6889922 DOI: 10.1148/radiol.2019190406] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Revised: 07/21/2019] [Accepted: 08/21/2019] [Indexed: 01/25/2023]
Abstract
Background The differential diagnosis of progressive supranuclear palsy (PSP) and Lewy body disorders, which include Parkinson disease and dementia with Lewy bodies, is often challenging due to the overlapping symptoms. Purpose To develop a diagnostic tool based on diffusion tensor imaging (DTI) to distinguish between PSP and Lewy body disorders at the individual-subject level. Materials and Methods In this retrospective study, skeletonized DTI metrics were extracted from two independent data sets: the discovery cohort from the Swedish BioFINDER study and the validation cohort from the Penn Frontotemporal Degeneration Center (data collected between 2010 and 2018). Based on previous neuroimaging studies and neuropathologic evidence, a combination of regions hypothesized to be sensitive to pathologic features of PSP were identified (ie, the superior cerebellar peduncle and frontal white matter) and fractional anisotropy (FA) was used to compute an FA score for each individual. Classification performances were assessed by using logistic regression and receiver operating characteristic analysis. Results In the discovery cohort, 16 patients with PSP (mean age ± standard deviation, 73 years ± 5; eight women, eight men), 34 patients with Lewy body disorders (mean age, 71 years ± 6; 14 women, 20 men), and 44 healthy control participants (mean age, 66 years ± 8; 26 women, 18 men) were evaluated. The FA score distinguished between clinical PSP and Lewy body disorders with an area under the curve of 0.97 ± 0.04, a specificity of 91% (31 of 34), and a sensitivity of 94% (15 of 16). In the validation cohort, 34 patients with PSP (69 years ± 7; 22 women, 12 men), 25 patients with Lewy body disorders (70 years ± 7; nine women, 16 men), and 32 healthy control participants (64 years ± 7; 22 women, 10 men) were evaluated. The accuracy of the FA score was confirmed (area under the curve, 0.96 ± 0.04; specificity, 96% [24 of 25]; and sensitivity, 85% [29 of 34]). Conclusion These cross-validated findings lay the foundation for a clinical test to distinguish progressive supranuclear palsy from Lewy body disorders. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Shah in this issue.
Collapse
Affiliation(s)
- Nicola Spotorno
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Sara Hall
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - David J. Irwin
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Theodor Rumetshofer
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Julio Acosta-Cabronero
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Andres F. Deik
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Meredith A. Spindler
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Edward B. Lee
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - John Q. Trojanowski
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Danielle van Westen
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Markus Nilsson
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Murray Grossman
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Peter J. Nestor
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Corey T. McMillan
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| | - Oskar Hansson
- From the Clinical Memory Research Unit, Department of Clinical
Sciences, Malmö, Lund University, Sölvegatan 19, 22100 Lund, Sweden
(N.S., S.H., D.v.W., O.H.); Penn Frontotemporal Degeneration Center, Department
of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pa (N.S., D.J.I., M.G., C.T.M.); Memory Clinic, Skåne
University Hospital, Malmö, Sweden (S.H., O.H.); Center for
Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, Pa (D.J.I., E.B.L., J.Q.T.); Department of
Diagnostic Radiology, Lund University, Lund, Sweden (T.R., D.v.W., M.N.);
Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology,
University College London, London, England (J.A.C.); Parkinson’s Disease
and Movement Disorders Center, Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, Pa (A.F.D., M.A.S.);
Alzheimer’s Disease Core Center, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pa (E.B.L., J.Q.T.); and Queensland Brain Institute, University of Queensland
and Mater Misericordiae, Brisbane, Queensland, Australia (P.J.N.)
| |
Collapse
|